Pharmaceutical

EC grants orphan medicinal product status to Rocket’s RP-A601

The EC has granted orphan medicinal product designation for Rocket Pharmaceuticals’ RP-A601 for PKP-2 related arrhythmogenic cardiomyopathy.

May 31, 2024 - 04:00
EC grants orphan medicinal product status to Rocket’s RP-A601
The EC has granted orphan medicinal product designation for Rocket Pharmaceuticals’ RP-A601 for PKP-2 related arrhythmogenic cardiomyopathy.
Read the original article

Tags:

Previous Article

AIFA’s horizon scanning 2024 predictions suggest an influx of ATMPs

Next Article

FDA approves Teva Pharmaceuticals’ AUSTEDO XR for TD and HD chorea

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novo Nordisk acquires Alkermes’s Irish plant to expand manufacturing capacity

Novo Nordisk acquires Alkermes’s Irish plant to expand ...

Dec 14, 2023

Opinion: Cost isn’t the only reason Medicare doesn’t cover Wegovy

Opinion: Cost isn’t the only reason Medicare doesn’t co...

Jan 8, 2024

Opinion: A seemingly small semantic issue is a major roadblock to develop treatments for rare diseases

Opinion: A seemingly small semantic issue is a major ro...

Jun 28, 2023